Advanced TP

SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC J. Nyman 1 , A. Hallqvist 1 , J.A. Lund 2 , O.T. Brustugun 3 , P. Bergström 4 , S. Friesland 5 , R. Lewensohn 5 , N. Drugge 6 , H. Rylander 1 , I. Lax 7

PFS at 36 mths: 61.1% SBRT 56.8 % CFRT

102 patients, (T1-2N0M0) NSCLC, significant comorbidity 9 Scandinavian centers rando: SBRT 3x 22 Gy; CFRT 35x 2 Gy primary endpoint: freedom from progression at 3 years

OS SBRT: 72 %, 65 % and 34 % OS CFRT: 84 %, 62 % and 34 % median survival: 41.3 vs. 42.1 months, Toxicity grade ≥ 3 SBRT 18 %, CFRT 16 % Any pneumonitis 16 % vs. 34 % in

Conclusion: There was a tendency to improved disease control rate at three years for the SBRT patients with similar overall survival and less toxicity compared to the conventional arm. SBRT is much more convenient for the patient and more cost effective and should be considered standard treatment for inoperable patients with stage I NSCLC

15 · 22. Januar 2016